UK launches subscription style model for antibiotics to encourage new development
In this article for the the BMJ, author Elisabeth Mahase looks into the UK's launch of a new subscription-style payment model for antibiotics, which aims to incentivise companies to invest in researching and developing new antibiotics in the face of growing antibiotic resistance.
The UK has launched its subscription style payment model for antibiotics, with the first two drugs to be selected and evaluated next year. The scheme will pay pharmaceutical companies upfront for their products, based on the value they provide to the NHS, rather than how much is used.
Our Jayasree K. Iyer is quoted in the article about the great potential such a service could have particularly if it is expanded to include a wide variety of antibiotics that are made available globally in order to reach those who need it most.